Topical Naringin for Hair Regrowth - Quick Reference Sheet
evipedia.ai ← Back

Topical Naringin for Hair Regrowth

Created on 07/31/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Topical naringin, a grapefruit-derived compound, is being explored as a scalp treatment for pattern hair loss. In the laboratory it switches on follicle growth signals, boosts local blood supply, and calms inflammation, and in one animal study matched a standard hair-loss drug. No human studies exist; it remains promising but unproven, with modest likely downsides. (Full Review)

Protocol

Concentration
4% (w/v)
Most effective strength tested; build up from 1% to assess tolerance
Application
Once daily
Thin layer to affected, dry scalp
Timing
Evening or morning
Leave undisturbed; avoid immediate washing
Time to effect
Visible regrowth
3–6 months
Minimum consistent daily use before judging results
Assessment
Every 8–12 weeks
Change judged over months, not weeks
Initial shedding
First weeks
Transient increased shedding possible as follicles resynchronize

Benefits

Contraindications
  • Known citrus or fragrance allergy
  • Active scalp inflammation, open lesions, or scarring alopecia
  • Pregnancy or breastfeeding
  • Children and adolescents (<18 years)
  • Narrow-therapeutic-index CYP3A4 substrate medications with large-area or broken-skin application
    •
Key Interactions
  • Concurrent topical hair actives (minoxidil, topical finasteride)
  • Irritant or penetration-enhancing topicals (retinoids such as tretinoin, alpha-hydroxy acids, strong alcohols)
  • Oral CYP3A4-metabolized medications (felodipine, simvastatin, cyclosporine, midazolam, triazolam)
  • Oral high-dose grapefruit/citrus bioflavonoid supplements
  • Additive-effect supplements (rosemary oil, procyanidins, caffeine-based topicals)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Skin irritation and contact dermatitis
    •
  • Speculative: Allergic contact sensitization; systemic drug-interaction risk from absorption; unknown long-term and cumulative safety
    •

Monitoring

Marker Target Why
Ferritin (iron stores) 40–70 ng/mL Common, correctable cause of shedding that can mask any benefit
Vitamin D (25-OH) 40–60 ng/mL Deficiency linked to hair-cycle disruption and poor follicle function
Thyroid (TSH) 1.0–2.0 mIU/L Thyroid imbalance causes diffuse hair loss a topical cannot overcome
Zinc (serum) 90–110 µg/dL Low zinc impairs the hair matrix and follicle protein synthesis
DHT / total testosterone Within age-appropriate reference Establishes the hormonal drive behind pattern loss

Cadence: Standardized photos at baseline then every 8–12 weeks; blood panel at baseline and again at 6–12 months

Qualitative Assessment

  • Shedding rate: whether daily hair fall decreases over the first few months
  • New regrowth: short, fine new hairs along the hairline or part
  • Hair density and part width: narrower part and denser coverage in matched photographs
  • Scalp comfort: absence of persistent redness, itching, or flaking
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.